Australian Biotech

Doug Swan, the executive general manager of wholesale and pharmacy services at Wesfarmers Health, said, “By investing in technology like myAPI, we’re ensuring pharmacy owners have 24/7 access to critical products and essential information at their fingertips.

The implementation group should not feel constrained by the recommendations, but it's tough to imagine any Government agreeing to one change without a second. The industry's leadership would understand this and be prepared given the timing.

New Zealand's Pharmac will fund Novo Nordisk's long-acting insulin therapy RYZODEG (insulin degludec and insulin aspart) from 1 May under an agreement that could benefit around 13,000 people in year one.

During the 2022 election campaign, Prime Minister Anthony Albanese and Mr Butler were unequivocal about their commitment to newborns and their parents.

Australia's election is two weeks in, and we're having trouble engaging. How positional power and 'expertism' can be confused and the value of a transparent and open forum.

Opthea (ASX:OPT) has updated investors following the recent termination of its COAST (Combination of OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab) Phase 3 clinical trials.

In the latest episode of the TrailblAZers podcast, Pharmacy Guild national president Professor Trent Twomey says that with 6,000 pharmacy locations and 40,000 registered pharmacists, the opportunity for the government is to support them to do more.

Dr David Hughes said Pharmac will widen access to medicines for blood cancers, bowel diseases, eczema and arthritis from 1 May through a bundle agreement with AbbVie.

A new report from a bipartisan organisation created by the US Congress says China is now the leader in global biotechnology and called for a policy and budget response.

Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has secured market approvals for its custom orthopaedic and cranial implants in Europe.